Value of Using Pioglitazone in Chronic Myeloid Leukemia Treatment

• Status: Completed
• Trial end date: 2021-04-15
• Target enrollment: 0
• Participant gender: All

Summary

Assessment of patients response and expression levels of CITED2 and HIF2a genes on adding pioglitazone to imatinib therapy.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mansoura University
• Treatments: Pioglitazone

Criteria

Inclusion Criteria:

• CML cases (BCR-ABL1 positive)

Exclusion Criteria:

• Accelerated or blastic crisis

• Atypical CML (BCR-ABL1 negative)

• Chronic myelomonocytic leukemia (CMML)

• Pregnant or breastfeeding females.

• Patients with severe organ dysfunction